Previous 10 | Next 10 |
The following slide deck was published by Blueprint Medicines Corporation in conjunction with this event. For further details see: Blueprint Medicines (BPMC) Presents At AAAAI Conference
Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting PR Newswire -- AYVAKIT achieved a statistically significant and clinically meaningful improvement in ...
Blueprint Medicines ( NASDAQ: BPMC ) announced Thursday that Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) has decided to end its collaboration agreement for Gavreto, an FDA-authorized therapy for certain cancer types caused by a genetic mutation called RET. Accordingly, Blueprint ( ...
Blueprint Medicines to Regain Global Rights to GAVRETO® (pralsetinib) from Roche PR Newswire CAMBRIDGE, Mass. , Feb. 23, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will regain global commercialization and developme...
Blueprint Medicines Corporation (BPMC) Q4 2022 Earnings Conference Call February 16, 2023, 08:00 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer C...
Blueprint Medicines press release ( NASDAQ: BPMC ): Q4 GAAP EPS of -$2.65 beats by $0.02 . Revenue of $38.78M (-63.8% Y/Y) beats by $5.26M . Revenues were $38.8 million for the fourth quarter of 2022, including $30.1 million of net product revenues from sales of AYVAKI...
Blueprint Medicines Reports Fourth Quarter and Full Year 2022 Results PR Newswire -- Achieved $204.0 million in total revenues in 2022, including $111.0 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues -- -- Continued progress towa...
Blueprint Medicines ( NASDAQ: BPMC ) shed ~2% pre-market Friday after announcing that the FDA placed a partial clinical hold on its Phase 1/2 VELA trial for cancer candidate BLU-222. According to verbal communication from the agency, the decision followed transient, reversible vis...
Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222 PR Newswire CAMBRIDGE, Mass. , Feb. 10, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) ve...
Blueprint Medicines to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023 PR Newswire CAMBRIDGE, Mass. , Feb. 9, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live co...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR Newswire CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call an...
2024-07-10 04:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...